TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Homozygous for the F508del mutation (F/F)~* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height~Key Exclusion Criteria:~* Clinically significant cirrhosis with or without portal hypertension~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* Solid organ or hematological transplantation~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TEZ/IVA (Type: ACTIVE_COMPARATOR): Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
- VX-659/TEZ/IVA TC (Type: EXPERIMENTAL): Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative High-dose Dexamethasone and Emergency Laparotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults (18 years or over) undergoing emergency laparotomy (laparotomy or laparoscopy) for following abdominal pathology:~   1. Primary perforated viscus (perforated ulcer, small intestine or colon)~  2. Primary intestinal obstruction ( small intestine or colon)~2. Provided verbal and written informed consent~3. Must speak and understand the Danish language~Exclusion Criteria:~1. Appendectomies, cholecystectomies, negative diagnostic laparoscopies/laparotomies, herniotomies without bowel resections, sub-acute internal hernias after gastric bypass surgery, sub-acute surgery for inflammatory bowel diseases.~2. Emergency re-operations after elective surgery owing to paralytic/obstructive ileus, perforated viscus, anastomotic leakage~3. Reoperation owing to fascial separation with no other abdominal pathology identified and sub-acute colorectal cancer-surgery will be excluded from the cohort. Sub-acute surgery is defined as surgery planned within 48 hours.~4. Intestinal Ischemia~5. intraabdominal bleeding~6. Traumas, gynecological, urogenital and other vascular pathology, pregnant participants.~7. Dementia and/or cognitive dysfunction (diagnosed).~8. Participants not oriented in time, place and person~9. Insuline treatment for diabetes mellitus type I and II~10. Current treatment with systemic glucocorticoids or immune suppressive treatment ( apart from inhalation steroids)~11. Allergies to trial medicine~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intestinal obstruction, Dexamethasone 1 mg/kg (Type: ACTIVE_COMPARATOR): Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
- Intestinal obstruction, PLACEBO (Type: PLACEBO_COMPARATOR): Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
- Perforated viscus, Dexamethasone 1 mg/kg (Type: ACTIVE_COMPARATOR): Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
- Perforated viscus, PLACEBO (Type: PLACEBO_COMPARATOR): Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent.~* Have severe or very severe AA, as determined by all of the following:~  * Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by SALT (AA-IGA of 3 or 4) at screening and baseline.~ * No spontaneous improvement over the past 6 months.~ * Current episode of severe or very severe AA of less than 8 years. Note: participants who have severe or very severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.~* Male or nonpregnant, nonbreastfeeding female participants.~Exclusion Criteria:~* Primarily diffuse type of AA.~* Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA.~* Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 4 Milligram (mg) Baricitinib (Type: EXPERIMENTAL): Participants received one 4 mg Baricitinib tablet administered orally, every day (QD) one placebo tablet administered orally QD to maintain blind.
- 2 mg Baricitinib (Type: EXPERIMENTAL): Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain blind.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received two placebo tablets administered orally QD to maintain the blind.
- 4 mg Baricitinib Maximum Extended Enrollment (MEE) (Type: EXPERIMENTAL): Participants received one 4 mg Baricitinib tablet administered orally, every day (QD) one placebo tablet administered orally QD to maintain blind.
- 2 mg Baricitinib MEE (Type: EXPERIMENTAL): Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain blind.
- Placebo MEE (Type: PLACEBO_COMPARATOR): Participants received two placebo tablets administered orally QD to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Office Blood Pressure (BP): Sitting diastolic blood pressure (SDBP)100-109 mmHg (inclusive) and sitting systolic blood pressure (SSBP) \< 180 mmHg after a 2 week placebo run-in period~* Home Blood Pressure: diastolic blood pressure (DBP)at home ≥ 85 mmHg in the last week of the placebo run-in period~* Normal Electrocardiogram (ECG), first degree Atrioventricular block or other changes not considered clinically significant~Exclusion Criteria:~* Secondary or severe hypertension~* History of cerebro- or cardiovascular complications~* Type 1 or Type 2 diabetes on drug treatment~* Severe renal or hepatic insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Lercanidipine 10 mg (Type: EXPERIMENTAL): None
- Lercanidipine 20 mg (Type: EXPERIMENTAL): None
- Enalapril 10 mg (Type: EXPERIMENTAL): None
- Enalapril 20 mg (Type: EXPERIMENTAL): None
- Lercanidipine 10 mg/Enalapril 10 mg (Type: EXPERIMENTAL): None
- Lercanidipine 10mg/Enalapril 20 mg (Type: EXPERIMENTAL): None
- Lercanidipine 20mg/Enalapril 10 mg (Type: EXPERIMENTAL): None
- Lercanidipine 20mg/Enalapril20mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 2-17 years of age~* Systemic juvenile idiopathic arthritis with \>= 6 months persistent activity~* Presence of active disease (\>=5 active joints, or \>=2 active joints + fever + steroids)~* Inadequate clinical response to nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids due to toxicity or lack of efficacy~Exclusion Criteria:~* Wheelchair-bound or bed-ridden~* Any other autoimmune, rheumatic disease or overlap syndrome other than systemic juvenile idiopathic arthritis~* Intravenous long-acting corticosteroids or intra-articular corticosteroids within 4 weeks of baseline, or throughout study~* Disease-modifying antirheumatic drugs (DMARDs), other than methotrexate~* Previous treatment with tocilizumab

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating a Telephone-Based Smoking Cessation Program Among People in the Military (The AFIII Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Department of Defense healthcare beneficiary~* Has smoked five or more cigarettes per day for at least 1 year before study entry~* Must be at least eighteen years old~Exclusion Criteria:~* Known allergy or sensitivity to nicotine replacement therapy~* No telephone~* Inability to understand consent procedures~* Basic Military Trainee

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Proactive group (Type: EXPERIMENTAL): Research study staff will contact participant to initiate the program. Half of participants will be randomized to the proactive condition and the other half to the reactive conditions.
- Reactive group (Type: EXPERIMENTAL): Participant will contact the research study staff to initiate the program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~- Participants receiving a lipid-lowering treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive participants with primary hypercholesterolemia if they are likely to have low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the end of the 6-week run-in treatment period on atorvastatin therapy~OR~- Participants with primary hypercholesterolemia treated with stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening and likely to have low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the screening visit.~Exclusion criteria:~1. LDL-C \< 100 mg/dL (\< 2.59 mmol/L) at Week -1 (V1):~   * After the run-in period on atorvastatin 10 mg for participants receiving a lipid lowering treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 6 weeks prior to the screening period, or drug naive participants.~   OR~  * At the first visit for participants who are being treated with atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening visit.~2. Participants not previously instructed on a cholesterol-lowering diet.~3. Participants with type 1 diabetes.~4. Participants with type 2 diabetes treated with insulin.~5. Participants with type 2 diabetes and with an HbA1c ≥ 8.5% at screening visit (considered poorly controlled).~6. Laboratory findings measured before randomization:~   * Triglycerides (TG) \> 350 mg/dL (\> 3.95 mmol/L) at screening visit.~  * Positive serum or urine pregnancy test in females of childbearing potential.~7. Pregnant or breast-feeding women.~8. Women of childbearing potential with no effective contraceptive method.~The above information is not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + Atorvastatin 80 mg (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) subcutaneous (SC) administration every 2 weeks (Q2W) in combination with atorvastatin 80 mg orally once daily for 8 weeks.
- Alirocumab + Atorvastatin 10 mg (Type: EXPERIMENTAL): Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 10 mg orally once daily for 8 weeks.
- Alirocumab + Atorvastatin 80 mg (Type: EXPERIMENTAL): Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 80 mg orally once daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~You may be eligible for this study if you:~* Are an HIV-positive woman over 13 years old (need consent if under 18).~* Have lost weight over the past 12 months.~* Are able to eat almost enough to maintain your current weight.~* Agree to practice abstinence or use effective methods of birth control.~* Are on a stable anti-HIV drug regimen or have not been on any anti-HIV drug regimen for the past 30 days.~Exclusion Criteria~You will not be eligible for this study if you:~* Are allergic to nandrolone.~* Have a history of cervical cancer, diabetes, cardiomyopathy or congestive heart failure, or are taking certain medications.~* Have an active opportunistic (HIV-associated) infection or another major illness within 30 days of study entry.~* Have an abnormal PAP smear.~* Have difficulty eating (are on tube-feeding, for example).~* Have severe nausea, vomiting, or diarrhea.~* Have Kaposi's sarcoma (unless stable) or are receiving chemotherapy or radiation for any type of cancer.~* Are pregnant or breast-feeding.

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a 2-year history of seasonal allergic rhinitis~* Has a positive skin test response to a local seasonal allergen (current, or performed in investigator's office within the past year)~* Is in good health and free of any unstable, clinically-significant disease, other than allergic rhinitis, that would interfere with the study schedule or evaluation of seasonal allergic rhinitis~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* Women of childbearing potential who are not using an acceptable form of birth control~* Has asthma that requires therapy with inhaled or systemic corticosteroids, cromolyn, or nedocromil~* Has significant renal, hepatic, neurologic, cardiovascular, hematologic, metabolic, cerebrovascular, respiratory, gastrointestinal, or other significant medical illness or disorder which, in the judgment of the investigator, could interfere with the study, or required treatment which might interfere with the study~* Is on immunotherapy with the exception of maintenance therapy~* Has a clinically significant upper respiratory or sinus infection~* Has used an investigational drug within the previous 30 days~* Has nasal structural abnormalities, including large nasal polyps and marked septal deviation, that significantly interfere with nasal air flow~* Has a history of multiple drug allergies or an allergy to antihistamines or corticoids~* Has dependence upon nasal, oral or ocular decongestants, or nasal topical antihistamines, in the opinion of the investigator~* Has rhinitis medicamentosa~* Is using of any chronic medication which could affect the course of seasonal allergic rhinitis

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mometasone furoate nasal spray (Type: EXPERIMENTAL): Participants administered mometasone furoate nasal spray 200 mcg once daily (QD), as two 50 mcg sprays per nostril, for 14 consecutive days.
- placebo nasal spray (Type: PLACEBO_COMPARATOR): Participants administered placebo nasal spray QD, as two placebo sprays per nostril, for 14 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stable CAD, defined as stable angina pectoris of class 1-3 by CCS (Canadian Cardiovascular Society) classification;~* Previously or newly diagnosed essential hypertension~* Age 18 to 79 years old;~* Informed consent of the patient for participation in the program;~* Decision of the doctor to prescribe bisoprolol/perindopril FDC before the inclusion in the program in accordance to the instruction for use.~Exclusion Criteria:~* Stable angina pectoris, class 4;~* History of myocardial infarction or cerebrovascular event within the past 3 months;~* Unstable angina within the past 6 months;~* Chronic heart failure classes 3-4 (NYHA);~* Type 1 diabetes mellitus or decompensated type 2 diabetes mellitus;~* Any serious decompensated concomitant diseases requiring the regular medical therapy;~* Inability to understand the essence of the program and follow the recommendations;~* Contraindications to beta-blockers or ACE inhibitors using;~* Participation of the patient in other trials in the present time or within 30 days before the start of observational program.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- the patients with HT and concomitant stable CAD (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Open-Label~* A diagnosis of Bipolar I Disorder, Most recent episode Manic (296.4x), or Bipolar I Disorder, Most Recent Episode Depressed (296.5x), or Bipolar I Disorder, Most recent Episode Mixed (296.6x), with or without psychotic features, as defined by Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV)~* At least 1 manic, depressed, or mixed episode in the 2 years prior to the index episode.~* Able to understand and comply with the requirements of the study.~Exclusion Criteria:~Open-Label~* Diagnosis of an anxiety disorder as defined by DSM-IV, which was treated with medication within the past year.~* Known intolerance or lack of response to quetiapine fumarate or to the assigned mood stabilizer, as judged by the investigator.~* Previously randomized into this study or D1447C00126

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years; CHF with New York Heart Association class II-IV; left ventricular ejection fraction ≤ 35%; on beta blockers~Exclusion Criteria:~* Potassium \> 5.2 mmol/l; estimated glomerular filtration rate \< 30 ml/min/1.73 m2; systolic blood pressure \<100 mmHg or \> 180 mmHg; history of intolerance to recommended target doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 Condensed (Type: EXPERIMENTAL): Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks
- LCZ696 Conservative (Type: EXPERIMENTAL): Up-titration to LCZ696 200 mg bid over 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete